News | August 12, 2009

FDA Medical Device, Radiological Health Regulator Resigns

Daniel Schultz, M.D., director of the FDA Center for Devices and Radiological Health

August 12, 2009 - The Food and Drug Administration's (FDA) top medical-device regulator, Daniel Schultz, M.D., director of the FDA Center for Devices and Radiological Health, announced his resignation.

While Dr. Schultz said it was a mutual agreement with FDA Commissioner Margaret Hamburg, the decision followed internal dissent over device-approval decisions that the regulator's critics said were too friendly to industry.

Dr. Schultz has worked at the FDA's Center for Devices and Radiological Health for 15 years and led it for the past five years. However, concerns over Dr. Schultz’s decisions surfaced two years ago when Sen. Chuck Grassley (R- Iowa) held hearings on Dr. Schultz's approval of a nerve stimulation device to treat depression, irrespective of objections from multiple FDA doctors. The senator again opened an investigation into a knee-surgery device made by ReGen Biologics Inc., also approved by Dr. Schultz despite numerous objections from FDA scientists and reviewers.

A year ago, the House Energy and Commerce Committee launched an investigation into allegations by at least eight FDA scientists that agency managers coerced those in the medical device division into approving products despite serious safety and effectiveness concerns.

The investigation was prompted by a letter released publicly from “a large group of scientists and physicians” within the FDA's Center for Devices and Radiological Health (CDRH), dated Oct. 14, 2008, said Committee Chair John Dingell (D-Mich.) and Oversight and Investigations Subcommittee Chair Bart Stupak (D-Mich.) According to the statement, the letter describes CDRH managers that have “corrupted and interfered with the scientific review of medical devices.”

The statement went on to say that the committee has been “provided with compelling evidence to support the charges that senior managers within CDRH ‘ordered, intimidated and coerced FDA experts to modify their scientific reviews, conclusions and recommendations in violation of the law.'”

The scientists claim that they were threatened with removal or negative performance reviews if they did not modify their scientific data to obscure unscientific clinical and technical data submitted by device companies and legal violations, including a lack of informed consent from study participants.

For more information: www.fda.gov

Related Content

Siemens Healthineers, Florida Hospital Collaborate to Improve Health Care Outcomes
News | CT Angiography (CTA) | January 23, 2018
January 23, 2018 – Siemens Healthineers and Florida Hospital, part of Adventist Health System, have announced a multi
CT Shows Enlarged Aortas in Former Pro Football Players

3-D rendering from a cardiac CT dataset demonstrating mild dilation of the ascending aorta.

News | Computed Tomography (CT) | January 11, 2018
Former National Football League (NFL) players are more likely to have enlarged aortas, a condition that may put them at...
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.
News | Business | January 08, 2018
Canon Inc. and Canon Medical Systems Corp. announced the official corporate name (trade name) change of Canon Group...
New International Report Provides Comprehensive Guide to Imaging in Chagas Heart Disease
News | Cardiovascular Ultrasound | January 03, 2018
Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis
News | CT Angiography (CTA) | December 28, 2017
HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five...
Siemens Healthineers Strengthens CT Portfolio With Four New Systems at RSNA 2017

The Somatom Force with the new FAST 3-D Camera

Technology | Computed Tomography (CT) | December 14, 2017
Siemens Healthineers introduced four new computed tomography (CT) scanners across two platforms at the 2017...
Toshiba Medical Introduces Aquilion Prime SP CT System at RSNA 2017
Technology | Computed Tomography (CT) | December 13, 2017
Toshiba Medical, a Canon Group company, introduced its new Aquilion Prime SP computed tomography (CT) system at the...
Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient

MRI of the brain performed on the Galan 3T utilizing the 32-channel Head SPEEDER Coil

Technology | Magnetic Resonance Imaging (MRI) | December 11, 2017
Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition with the all-new Saturn X...
Overlay Init